Product Images Fluticasone Propionate And Salmeterol

This text is a product description for a medication called Fluticasone Prop and Salmeterol Inh Powder, which is a generic version of Advair HFA. Each blister contains 250mcg fluticasone propionate USP and 72.5mcg salmeterol, with lactose. The medication is manufactured by Hikma Pharmaceuticals USA Inc., and is for oral inhalation only. It needs to be stored in a dry place at 20° to 25°C and out of the reach of children. The text also includes instructions in Spanish and cautions that federal law prohibits the transfer of this drug to anyone other than the patient for whom it was prescribed. There are also additional details such as the package size, expiration date, lot/batch numbers, and insurance NDC.*

Fluticasone Propionate and Salmeterol Inhalation Powder is a medication that contains 250 mcg/50 mcg of Fluticasone Propionate and Salmeterol. The medication is used twice daily to improve FEV in patients with respiratory problems. The study shows the percentage change in FEV measurements taken at different endpoints - day 1, week 1, week 2, week 4, week 6, and endpoint. Two other groups were created to compare the results - one group taking only Fluticasone Propionate and the other taking a placebo. The study was conducted on 183 patients.*

This appears to be a chart displaying data related to a clinical trial involving the inhalation powder Fluticasone Propionate and Salmeterol, with a comparison to the drug Salmeterol and a placebo. The baseline and endpoint Forced Expiratory Volume (FEV) measurements are provided in milliliters. The chart shows a comparison of the three treatments over several weeks, with an increase in FEV observed in the group who received Fluticasone Propionate and Salmeterol Inhalation Powder, as compared to the other groups.*

This text appears to be a table that includes the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder in comparison to fluticasone propionate alone, salmeterol alone, and a placebo over a period of 12 weeks. The table includes the percentage of participants experiencing positive results at each time point.*

This appears to be a graph showing the change in FEV4 over time for four different treatments: Fluticasone Propionate and Salmeterol Inhalation Powder, Salmeterol alone, Fluticasone Propionate alone, and a placebo. The treatments were administered twice daily for up to 12 hours on the first treatment day. No additional context or information is available.*

This is a chart showing the percent change in forced expiratory volume (FEV) relative to the Day 1 baseline for different treatment groups using fluticasone propionate and salmeterol inhalation powder and placebo. The chart shows data for three different time points: Day 1 Baseline, Week 12 Baseline and Last Treatment Day. The N-value for each treatment group is also shown.*

The text describes the parts of an object, including an "Outer Case Counter," a "Thumb Grip," and a "Mouthpiece." It is not clear what object these parts belong to, so further information is not available.*